

Disclosure

A reference is made to the disclosure made by National Pharmaceutical Industries SAOG (under conversion) (the “**Company**”) on the 12th and 13th of September 2018 concerning the conversion of the Company from SAOG to SAOC following initial approval being granted by the Capital Market Authority (“**CMA**”) to the said conversion on the 10th of September 2018.

As mentioned in the previous disclosure, the Company’s majority shareholders viz. Oman Investment Fund Holding Co LLC and Middle East Investment LLC (together “**Majority Shareholders**”) offered to purchase the shares held by the minority shareholders of the Company. United Securities LLC has been appointed as broker to complete the purchase of any shares offered for sale by minority shareholders during the purchase offer period, which commenced on the 2nd of October 2018 and is due to close on the 31st of October 2018 (“**Offer Period**”).

During the Offer Period the Company has received some response from minority shareholders for selling their shares to the Majority Shareholders.

In order for all the minority shareholders to have sufficient time to complete and submit their applications, the Company on the 28th of October 2018 requested the Capital Market Authority (“**CMA**”) to allow an extension of the Offer period for 7 days from the 01st of November 2018 to the 08th of November 2018, which extension was granted by the CMA on the 29th of October 2018.

In light of the extension granted by the CMA, the purchase Offer Period shall now expire on the 8th of November 2018.

The minority shareholders may contact M/s United Securities LLC (P.O. Box 2566, PC 112, Ruwi, Muscat, Sultanate of Oman, Tel: 00968-24763337, Fax: 00968-24503750, Email: ayman@usoman.com) in relation to the purchase offer.

#